Air Pollution May Contribute to Lung Cancer in Never-smokers
|
Although lung cancer has long been considered a smoker's disease, a new study by Moores Member Ludmil Alexandrov, PhD, identifies genomic links between exposure to environmental pollution and the development of lung cancer. Learn More>>
|
Alice L. Yu, MD, PhD Receives Advances in Neuroblastoma Research Association Lifetime Achievement Award
|
Moores Member and pediatric oncologist Dr. Alice Yu has been recognized for research, which has transformed neuroblastoma treatment through the development of anti-GD2 antibody therapy that targets the disialoganglioside GD2. Learn More>>
|
|
|
| Effect of phosphorylation barcodes on arrestin binding to a chemokine receptor
|
Tracy M. Handel, PhD (Solid Tumor Therapeutics)
|
|
|
| Mitochondrial DNA oxidation propagates autoimmunity by enabling plasmacytoid dendritic cells to induce TFH differentiation
|
Elina Zuniga, PhD (Cancer Biology and Signaling), Hal M. Hoffman, MD (Structural and Functional Genomics), and Michael Karin, PhD (Solid Tumor Therapeutics)
|
|
|
| AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials
|
Rohit Loomba, MD (Cancer Control)
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
|
This Notice of Funding Opportunity will support biomedical, behavioral, and social science investigators in the early stages of establishing independent careers in tobacco regulatory research that can inform FDA regulations on tobacco product manufacturing, distribution, and marketing to protect public health.
Submission Deadline: October 18, 2025
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
|
|
DS3201-330: A Multicenter, Randomized, Open-Label, Phase Ib/II Trial of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Tumor Proportion Score 50% or Over Without Actionable Genomic Alterations
PI: Lyudmila Bazhenova, MD
NCT ID: NCT06644768
|
|
|
|
